Prelude Therapeutics Q3 loss widens to $30.7M; CFO and CMO depart; cash $320.9M

Prelude Therapeutics Inc

Q3 net loss $30.7M ($0.66/sh) vs $16.8M loss in Q3 2020; cash, equivalents and securities $320.9M.
CFO Brian Piper resigns effective Nov 19; Laurent Chardonnet appointed CFO from Nov 29.
CMO Dr. David Mauro mutually agreed to depart Nov 9; search for successor ongoing.
PRT2527 IND cleared; Phase 1 trial to start by year-end; PRT543/811 expansion data expected in 2022.
Retention bonus of $200k approved for EVP Deborah Morosini if employed through Nov 30, 2022.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Laurent Chardonnet

Chief Financial Officer

PRLD · Prelude Therapeutics Inc

Effective: 2021-11-29
Filed: November 12, 2021, 6:59 PM ET

On November 5, 2021, the Board of Directors of the Company (the “Board”) appointed Laurent Chardonnet as the Chief Financial Officer of the Company, including as the “principal financial officer” and “principal accounting officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective on or about November 29, 2021.

Departed

Brian Piper

Chief Financial Officer

PRLD · Prelude Therapeutics Inc

Effective: 2021-11-19
Successor: Laurent Chardonnet
Filed: November 12, 2021, 6:59 PM ET

On November 5, 2021, Brian Piper, the Chief Financial Officer of the Company, notified the Company that he will be resigning from the Company, effective November 19, 2021, to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Laurent Chardonnet was appointed as Chief Financial Officer at Prelude Therapeutics Inc.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 5, 2021, the Board of Directors of the Company (the “Board”) appointed Laurent Chardonnet as the Chief Financial Officer of the Company, including as the “principal financial officer” and “principal accounting officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective on or about November 29, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Piper resigned as Chief Financial Officer at Prelude Therapeutics Inc.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On November 5, 2021, Brian Piper, the Chief Financial Officer of the Company, notified the Company that he will be resigning from the Company, effective November 19, 2021, to pursue other opportunities.

View on SEC.gov

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0001564590-21-056478

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.